[go: up one dir, main page]

HRP20110957T1 - Derivati kinolina kao inhibitori fosfodiesteraza - Google Patents

Derivati kinolina kao inhibitori fosfodiesteraza Download PDF

Info

Publication number
HRP20110957T1
HRP20110957T1 HR20110957T HRP20110957T HRP20110957T1 HR P20110957 T1 HRP20110957 T1 HR P20110957T1 HR 20110957 T HR20110957 T HR 20110957T HR P20110957 T HRP20110957 T HR P20110957T HR P20110957 T1 HRP20110957 T1 HR P20110957T1
Authority
HR
Croatia
Prior art keywords
6alkyl
optionally substituted
aryl
heteroaryl
4alkyl
Prior art date
Application number
HR20110957T
Other languages
English (en)
Inventor
Robert Baldwin Ian
David Barker Michael
William Dean Anthony
David Eldred Colin
Evans Brian
Lisa Gough Sharon
Barry Guntrip Stephen
Nicole Hamblin Julie
Holman Stuart
Jones Paul
Kristian Lindvall Mika
James Lunniss Christopher
Jane Redfern Tracy
Judith Redgrave Alison
Edward Robinson John
Woodrow Michael
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311688A external-priority patent/GB0311688D0/en
Priority claimed from GB0326187A external-priority patent/GB0326187D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20110957T1 publication Critical patent/HRP20110957T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Farmaceutski pripravak namijenjen za inhalacijsku primjenu, naznačen time što sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol: gdje: R1 jeC1-6alkil; C3-7cikloalkil ili C3-7cikloalkil(C1-4alkil)-, gdje je C3-7cikloalkil izborno supstituiran s jednim ili više supstituenata, koje se bira između =O i OH; C4-7cikloalkil, kondenziran s arilnim prstenom; Aril ili aril(C1-6alkil)-, gdje je aril izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkila, C1-6alkilCONR6-, C1-6alkilCO-, halogena, -CF3, -(CH2)mOH, -OCF3, C1-6alkoksi-, C1-6alkoksi(C1-4alkil)-, C1-6alkoksiC2-6alkoksi-, C1-6alkoksikarbonila, -CN, R4R5NCO, R7R8N-, R9R10NCONR11, HO(CH2)2-6O-, R12R13NSO2(CH2)m-, (4-morfolinil)C2-6alkoksi, -NR14SO2C1-6alkil, ariloksi, heteroarila (izborno supstituiranog s C1-6alkilom), CO2H, R21R22N(C1-4alkil)-, C1-6alkoksiCONR23(CH2)m-, arila (izborno supstituiranog s C1-6alkilom); Aril, kondenziran s C4-7cikloalkilnim prstenom, gdje je cikloalkilni prsten izborno supstituiran s jednim ili više =O; Aril, kondenziran s heterociklilnim prstenom, gdje je heterociklilni prsten izborno supstituiran s jednim ili više supstituenata, koje se bira između =O, -COC1-4alkila, C1-4alkila; Heteroaril ili heteroaril(C1-6alkil)-, gdje je heteroaril izborno supstituiran s jednim ili više supstituenata, koje se bira između: C1-6alkila, aril(C1-4alkil), C1-6alkoksi, halogena, C1-6alkoksiCO; iliHeterociklil, izborno kondenziran s arilnim ili heteroarilnim prstenom; R2 je vodik ili C1-6alkil; R34 je skupina formule: gdje R3 jeC1-6alkil, izborno supstituiran s jednim ili više supstituenata, koje se bira između -OH, -NR16COR15, -NR17R18, -CO2R24, C1-6alkoksiCONR25-, -CONR26R27, C1-6alkoksi-, C1-6alkilSO2NR33-, ili skupina s jednom od sljedećih formula: C3-7cikloalkil; Aril ili aril(C1-6alkil)-, gdje je aril izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkil-, halogen-, C1-6alkoksi-, -CO2R28, -CH2CO2H, -OH, arila (izborno supstituiranog s C1-6alkoksi skupinom), heteroarila, -CONR29R30, C3-7cikloalkoksi, C3-7cikloalkil(C1-6alkoksi)-, -CF3;Heteroaril ili heteroaril(C1-6alkil)-, gdje je heteroaril izborno supstituiran s jednomm ili više C1-6alkilnih ili -CONR29R30 skupina; iliHeterociklil, koji je izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkil-, C1-6alkilCO-, C3-7cikloalkilCO-, heteroarilCO- (izborno supstituiranog s jednom ili više C1-4alkilnih skupina), C1-6alkoksiCO-, arilCO-, R31R32NCO-, C1-6 salkilSO2-, arilSO2, -heteroarilSO2 (izborno supstituiranog s jednim ili više C1-4alkilnih ili C1-4alkilCONH- skupina); heterociklil je vezan na S(=O)n ostatak preko atoma ugljika; m je 0-6; n je 0, 1 ili 2; R19 je vodik ili C1-6alkil; R20 je vodik, C1-6alkil, halogen ili C1-6alkoksi; svaki od R4-18, R21-25, R28 i R31-33 neovisno predstavlja H, C1-6alkil; R26 i R27 neovisno predstavljaju H, C1-6alkil, C3-7cikloalkil ili heterociklil; R29 i R30 neovisno predstavljaju H, C1-6alkil, izborn

Claims (11)

1. Farmaceutski pripravak namijenjen za inhalacijsku primjenu, naznačen time što sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol: [image] gdje: R1 je C1-6alkil; C3-7cikloalkil ili C3-7cikloalkil(C1-4alkil)-, gdje je C3-7cikloalkil izborno supstituiran s jednim ili više supstituenata, koje se bira između =O i OH; C4-7cikloalkil, kondenziran s arilnim prstenom; Aril ili aril(C1-6alkil)-, gdje je aril izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkila, C1-6alkilCONR6-, C1-6alkilCO-, halogena, -CF3, -(CH2)mOH, -OCF3, C1-6alkoksi-, C1-6alkoksi(C1-4alkil)-, C1-6alkoksiC2-6alkoksi-, C1-6alkoksikarbonila, -CN, R4R5NCO, R7R8N-, R9R10NCONR11, HO(CH2)2-6O-, R12R13NSO2(CH2)m-, (4-morfolinil)C2-6alkoksi, -NR14SO2C1-6alkil, ariloksi, heteroarila (izborno supstituiranog s C1-6alkilom), CO2H, R21R22N(C1-4alkil)-, C1-6alkoksiCONR23(CH2)m-, arila (izborno supstituiranog s C1-6alkilom); Aril, kondenziran s C4-7cikloalkilnim prstenom, gdje je cikloalkilni prsten izborno supstituiran s jednim ili više =O; Aril, kondenziran s heterociklilnim prstenom, gdje je heterociklilni prsten izborno supstituiran s jednim ili više supstituenata, koje se bira između =O, -COC1-4alkila, C1-4alkila; Heteroaril ili heteroaril(C1-6alkil)-, gdje je heteroaril izborno supstituiran s jednim ili više supstituenata, koje se bira između: C1-6alkila, aril(C1-4alkil), C1-6alkoksi, halogena, C1-6alkoksiCO; ili Heterociklil, izborno kondenziran s arilnim ili heteroarilnim prstenom; R2 je vodik ili C1-6alkil; R34 je skupina formule: [image] gdje R3 je C1-6alkil, izborno supstituiran s jednim ili više supstituenata, koje se bira između -OH, -NR16COR15, -NR17R18, -CO2R24, C1-6alkoksiCONR25-, -CONR26R27, C1-6alkoksi-, C1-6alkilSO2NR33-, ili skupina s jednom od sljedećih formula: [image] C3-7cikloalkil; Aril ili aril(C1-6alkil)-, gdje je aril izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkil-, halogen-, C1-6alkoksi-, -CO2R28, -CH2CO2H, -OH, arila (izborno supstituiranog s C1-6alkoksi skupinom), heteroarila, -CONR29R30, C3-7cikloalkoksi, C3-7cikloalkil(C1-6alkoksi)-, -CF3; Heteroaril ili heteroaril(C1-6alkil)-, gdje je heteroaril izborno supstituiran s jednomm ili više C1-6alkilnih ili -CONR29R30 skupina; ili Heterociklil, koji je izborno supstituiran s jednim ili više supstituenata, koje se bira između C1-6alkil-, C1-6alkilCO-, C3-7cikloalkilCO-, heteroarilCO- (izborno supstituiranog s jednom ili više C1-4alkilnih skupina), C1-6alkoksiCO-, arilCO-, R31R32NCO-, C1-6 salkilSO2-, arilSO2, -heteroarilSO2 (izborno supstituiranog s jednim ili više C1-4alkilnih ili C1-4alkilCONH- skupina); heterociklil je vezan na S(=O)n ostatak preko atoma ugljika; m je 0-6; n je 0, 1 ili 2; R19 je vodik ili C1-6alkil; R20 je vodik, C1-6alkil, halogen ili C1-6alkoksi; svaki od R4-18, R21-25, R28 i R31-33 neovisno predstavlja H, C1-6alkil; R26 i R27 neovisno predstavljaju H, C1-6alkil, C3-7cikloalkil ili heterociklil; R29 i R30 neovisno predstavljaju H, C1-6alkil, izborno supstituiran s OH; R7 i R8, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten; R9 i R10, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten; R17 i R18, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten, poput morfolina; R21 i R22, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten; R26 i R27, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten; R29 i R30, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten, poput morfolina; R31 i R32, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što spoj formule (I) je: 6-({3-[(dimetilamino)karbonil]fenil}sulfonil)-8-metil-4-{[3-(metiloksi)fenil]amino}-3-kinolinkarboksamid.
3. Farmaceutski pripravak u skladu s patentnim zahtjevima 1-2, naznačen time što je suhi prah.
4. Farmaceutski pripravak u skladu s patentnim zahtjevima 1-3, naznačen time što dodatno sadrži muskarinski antagonist.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što muskarinski antagonist je ipatropijev bromid, oksitropijev bromid ili tiotropijev bromid.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što muskarinski antagonist je tiotropijev bromid.
7. Farmaceutski pripravak u skladu s patentnim zahtjevima 1-6, naznačen time što dodatno sadrži agonist β2-adrenoreceptora.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što agonist β2-adrenoreceptora je dugodjelujući agonist β2-adrenoreceptora.
9. Farmaceutski pripravak u skladu s patentnim zahtjevima 1-8, naznačen time što je namijenjen upotrebi u liječenju upalnih i/ili alergijskih bolesti.
10. Farmaceutski pripravak u skladu s patentnim zahtjevima 1-9, naznačen time što je namijenjen liječenju COPD.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je namijenjen liječenju astme.
HR20110957T 2003-05-21 2011-12-20 Derivati kinolina kao inhibitori fosfodiesteraza HRP20110957T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0311688A GB0311688D0 (en) 2003-05-21 2003-05-21 Compounds
GB0326187A GB0326187D0 (en) 2003-11-10 2003-11-10 Compounds

Publications (1)

Publication Number Publication Date
HRP20110957T1 true HRP20110957T1 (hr) 2012-01-31

Family

ID=33477765

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20080236T HRP20080236T3 (hr) 2003-05-21 2004-05-19 Kinolinski derivati kao inhibitori fosfodiesteraze
HR20110957T HRP20110957T1 (hr) 2003-05-21 2011-12-20 Derivati kinolina kao inhibitori fosfodiesteraza

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20080236T HRP20080236T3 (hr) 2003-05-21 2004-05-19 Kinolinski derivati kao inhibitori fosfodiesteraze

Country Status (30)

Country Link
US (4) US7566786B2 (hr)
EP (2) EP1944305B1 (hr)
JP (1) JP4625460B2 (hr)
KR (1) KR101144548B1 (hr)
CN (1) CN1823063B (hr)
AR (1) AR044401A1 (hr)
AT (2) ATE388148T1 (hr)
AU (1) AU2004240759B2 (hr)
BR (1) BRPI0410477A (hr)
CA (1) CA2526228C (hr)
CO (1) CO5700780A2 (hr)
CY (2) CY1108094T1 (hr)
DE (1) DE602004012260T2 (hr)
DK (2) DK1633748T3 (hr)
EG (1) EG24774A (hr)
ES (2) ES2374850T3 (hr)
HR (2) HRP20080236T3 (hr)
IL (1) IL171726A (hr)
IS (1) IS2581B (hr)
MA (1) MA27808A1 (hr)
MX (1) MXPA05012466A (hr)
NO (1) NO330754B1 (hr)
NZ (1) NZ543554A (hr)
PL (2) PL1633748T3 (hr)
PT (2) PT1944305E (hr)
RU (1) RU2335493C2 (hr)
SI (2) SI1633748T1 (hr)
TW (1) TWI328009B (hr)
WO (1) WO2004103998A1 (hr)
ZA (1) ZA200509319B (hr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0425572D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
GB0503955D0 (en) * 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
GB0505621D0 (en) * 2005-03-18 2005-04-27 Glaxo Group Ltd Novel compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
GB0605462D0 (en) * 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
EP2013185B1 (en) 2006-04-20 2012-05-30 Glaxo Group Limited Novel compounds
KR101441146B1 (ko) * 2006-04-28 2014-09-17 시오노기세야쿠 가부시키가이샤 Ｎｐｙ ｙ5 수용체 길항 작용을 갖는 아민 유도체
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
EP2379076B1 (en) * 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
KR101771193B1 (ko) 2009-04-30 2017-09-05 글락소 그룹 리미티드 Ｐｉ3­키나아제 억제제로서 옥사졸 치환된 인다졸
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
US8394829B2 (en) 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20130225524A1 (en) * 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
AU2012225735B2 (en) * 2011-03-04 2016-03-10 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
KR20140088887A (ko) * 2011-11-03 2014-07-11 머크 샤프 앤드 돔 코포레이션 mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CA3102531A1 (en) 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
KR20150118152A (ko) 2013-02-21 2015-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 퀴나졸린
RU2016112266A (ru) 2013-10-17 2017-11-20 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
CA2980484C (en) * 2015-03-24 2019-11-26 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
CN110461334A (zh) * 2016-12-22 2019-11-15 马福制药公司 增强或增加i型ifn产生的组合物和方法
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
WO2024153112A1 (zh) * 2023-01-17 2024-07-25 瑞石生物医药有限公司 Pde4抑制剂、其制备方法及其在医药上的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE46886B1 (en) 1977-05-17 1983-10-19 Allen & Hanburys Ltd Aminoalkyl-benzene derivatives
EP0048005A3 (de) * 1980-09-17 1983-01-19 ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
ES2112272T3 (es) * 1990-03-28 1998-04-01 Otsuka Pharma Co Ltd Derivado de quinolina, medicamento anti-ulceroso que contiene este derivado y produccion de este derivado.
US5214191A (en) 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0752853B1 (en) 1993-03-10 2005-09-21 Smithkline Beecham Corporation Human brain phosphodiesterase
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
ZA954940B (en) 1994-06-15 1996-12-17 Wellcome Found Enzyme inhibitors
BR9709105A (pt) * 1996-05-20 1999-08-03 Darwin Discovery Ltd Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
NZ334125A (en) 1996-09-25 2000-10-27 Zeneca Ltd Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
EP1042295B1 (en) 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
BRPI9914164B8 (pt) 1998-09-29 2021-05-25 American Cyanamid Co compostos de 3-ciano quinolina
KR100705142B1 (ko) 1998-09-29 2007-04-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린
AR028986A1 (es) 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
CA2367431C (en) 1999-03-15 2008-06-10 Abbott Laboratories 6-o-substituted macrolides having antibacterial activity
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
MXPA03002814A (es) 2000-09-29 2003-10-14 Glaxo Group Ltd Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias.
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7129225B2 (en) 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
CA2486989A1 (en) 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ES2374850T3 (es) 2012-02-22
CN1823063B (zh) 2010-07-14
BRPI0410477A (pt) 2006-05-30
KR101144548B1 (ko) 2012-05-11
NZ543554A (en) 2008-09-26
EP1633748B1 (en) 2008-03-05
EP1633748A1 (en) 2006-03-15
CA2526228C (en) 2010-08-03
CY1108094T1 (el) 2014-02-12
KR20060015278A (ko) 2006-02-16
PL1944305T3 (pl) 2012-03-30
CA2526228A1 (en) 2004-12-02
US20090312325A1 (en) 2009-12-17
IS8110A (is) 2005-10-31
NO20055421D0 (no) 2005-11-16
HK1092458A1 (en) 2007-02-09
NO20055421L (no) 2005-12-20
CY1112232T1 (el) 2015-12-09
HK1118274A1 (en) 2009-02-06
JP2007501264A (ja) 2007-01-25
DE602004012260D1 (hr) 2008-04-17
JP4625460B2 (ja) 2011-02-02
TWI328009B (en) 2010-08-01
US20060178416A1 (en) 2006-08-10
RU2335493C2 (ru) 2008-10-10
US7572915B2 (en) 2009-08-11
CO5700780A2 (es) 2006-11-30
CN1823063A (zh) 2006-08-23
DK1944305T3 (da) 2012-01-30
WO2004103998A1 (en) 2004-12-02
IL171726A (en) 2013-07-31
ATE388148T1 (de) 2008-03-15
PL1633748T3 (pl) 2008-07-31
ZA200509319B (en) 2007-02-28
PT1633748E (pt) 2008-05-20
AU2004240759A1 (en) 2004-12-02
US20070049570A1 (en) 2007-03-01
RU2005135016A (ru) 2006-06-27
EP1944305B1 (en) 2011-10-19
EP1944305A1 (en) 2008-07-16
MA27808A1 (fr) 2006-03-01
AR044401A1 (es) 2005-09-14
DE602004012260T2 (de) 2009-03-12
DK1633748T3 (da) 2008-06-30
TW200500358A (en) 2005-01-01
EG24774A (en) 2010-08-19
SI1633748T1 (sl) 2008-08-31
NO330754B1 (no) 2011-07-04
HRP20080236T3 (hr) 2008-06-30
ES2301993T3 (es) 2008-07-01
US7566786B2 (en) 2009-07-28
IS2581B (is) 2010-02-15
SI1944305T1 (sl) 2012-02-29
US20070142373A1 (en) 2007-06-21
MXPA05012466A (es) 2006-01-30
AU2004240759B2 (en) 2010-03-04
PT1944305E (pt) 2012-01-11
ATE529421T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
HRP20110957T1 (hr) Derivati kinolina kao inhibitori fosfodiesteraza
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
CA2445190A1 (en) Indole, azaindole and related heterocyclic amidopiperazine derivatives
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR048292A1 (es) Derivados de quinolina y composiciones farmaceuticas utiles para el tratamiento del cancer
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR010378A1 (es) Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios
AR045180A1 (es) Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
TW200700387A (en) 1-benzylindole-2-carboxamide derivatives
AR035795A1 (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de la enzima endopeptidasa neutra, uso de los mismos, procedimientos e intermediarios para su preparación y composiciones que contienen dichos inhibidores
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
PA8573501A1 (es) Derivados de benzoxazina y su empleo